The recent surge in investments into niche pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." https://ineslrsm063325.blogaritma.com/38116564/premium-stakeholder-pharma-the-risky-bet